Gupta allegedly purchased Epizyme shares while aware of that material non-public information and, after the announcement was made, sold the shares realizing approximately $260,000 in illegal ...

Epizyme overcame this issue with a new safety analysis, but there is always room for fresh issues to be uncovered during the FDA review. Epizyme holds global development and marketing rights to ...

The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart Epizyme and its cancer therapy Tazverik, in a deal valued at a little under $250 million. Ipsen is ...

Cancer is a big part of Ipsen’s growth strategy, evident in a series of business deals struck by the company in recent years ...

The Soft Tissue Sarcoma market is expected to surge due to the disease's increasing prevalence and awareness during the ...